Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy

Timothy E Albertson,1–3 Samuel W Bullick,1,3 Michael Schivo,1 Mark E Sutter2,3 1Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, 2Department of Emergency Medicine, School of Medicine, UC Davis, Sacramento, 3Department of Medicine, Veterans Administ...

全面介紹

書目詳細資料

發表在:	Drug Design, Development and Therapy
Main Authors:	Albertson TE, Bullick SW, Schivo M, Sutter ME
格式:	Article
語言:	英语
出版:	Dove Medical Press 2016-12-01
主題:	Fluticasone furoate / vilanterol trifenatate asthma long-acting beta2 agonist (LABA) inhaled corticosteroid (ICS) combined inhaler persistent asthma dry powder inhaler (DPI)
在線閱讀:	https://www.dovepress.com/spotlight-on-fluticasone-furoatevilanterol-trifenatate-for-the-once-da-peer-reviewed-article-DDDT